Leukotrienes in Pulmonary Arterial Hypertension

Overview

Journal Immunol Res

Specialty Allergy & Immunology

Date 2014 Feb 27

PMID 24570092

Citations 20

Authors

Wen Tian

Xinguo Jiang

Yon K Sung

Jin Qian

Ke Yuan

Mark R Nicolls

Affiliations

Soon will be listed here.

Abstract

Leukotrienes (LTs) are lipid mediators derived from the 5-lipoxygenase (5-LO) pathway of arachidonic acid metabolism and are markers and mediators of pulmonary inflammation. Research over the past two decades has established that LTs modulate inflammation in pulmonary arterial hypertension (PAH). The purpose of this review was to summarize the current knowledge of LTs in the pathophysiology of PAH and to highlight a recent study that advances our understanding of how leukotriene B4 (LTB4) specifically contributes to pulmonary vascular remodeling. The results of these studies suggest that pharmacological inhibition of LT pathways, especially LTB4, has high potential for the treatment of PAH.

Citing Articles

Exercise improves systemic metabolism in a monocrotaline model of pulmonary hypertension.

Poojary G, Vasishta S, Thomas R, Satyamoorthy K, Padmakumar R, Joshi M Sports Med Health Sci. 2024; 7(1):37-47.

PMID: 39649790 PMC: 11624410. DOI: 10.1016/j.smhs.2024.03.001.

The Emerging Therapeutic Role of Prostaglandin E2 Signaling in Pulmonary Hypertension.

Ye L, Wang B, Xu H, Zhang X Metabolites. 2023; 13(11).

PMID: 37999248 PMC: 10672796. DOI: 10.3390/metabo13111152.

Mechanism of Hypoxia-Mediated Smooth Muscle Cell Proliferation Leading to Vascular Remodeling.

Huang X, Akgun E, Mehmood K, Zhang H, Tang Z, Li Y Biomed Res Int. 2023; 2022:3959845.

PMID: 36593773 PMC: 9805398. DOI: 10.1155/2022/3959845.

Changes of Pulmonary Microhemodynamics in Experimental Pulmonary Thromboembolism after Pretreatment with K-Channel Activators.

Evlakhov V, Poyasov I, Berezina T Bull Exp Biol Med. 2022; 173(3):302-305.

PMID: 35844023 DOI: 10.1007/s10517-022-05538-8.

Dissecting the Regulation of Arachidonic Acid Metabolites by (Miq). Miq. in Spontaneously Hypertensive Rats and the Predictive Target sEH in the Anti-Hypertensive Effect Based on Metabolomics and Molecular Docking.

Gao L, Kong X, Wu W, Feng Z, Zhi H, Zhang Z Front Pharmacol. 2022; 13:909631.

PMID: 35712719 PMC: 9196077. DOI: 10.3389/fphar.2022.909631.

References

Shaafi R, Naccache P, Molski T, Borgeat P, Goetzl E . Cellular regulatory role of leukotriene B4: its effects on cation homeostasis in rabbit neutrophils. J Cell Physiol. 1981; 108(3):401-8. DOI: 10.1002/jcp.1041080314. View

Benza R, Miller D, Gomberg-Maitland M, Frantz R, Foreman A, Coffey C . Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010; 122(2):164-72. DOI: 10.1161/CIRCULATIONAHA.109.898122. View

Henderson W, Jorg A, Klebanoff S . Eosinophil peroxidase-mediated inactivation of leukotrienes B4, C4, and D4. J Immunol. 1982; 128(6):2609-13. View

Fels A, Pawlowski N, Cramer E, King T, COHN Z, Scott W . Human alveolar macrophages produce leukotriene B4. Proc Natl Acad Sci U S A. 1982; 79(24):7866-70. PMC: 347450. DOI: 10.1073/pnas.79.24.7866. View

Tamosiuniene R, Nicolls M . Regulatory T cells and pulmonary hypertension. Trends Cardiovasc Med. 2012; 21(6):166-71. PMC: 3401377. DOI: 10.1016/j.tcm.2012.05.004. View

Rubin L . Treatment of pulmonary arterial hypertension due to scleroderma: challenges for the future. Rheum Dis Clin North Am. 2008; 34(1):191-7. DOI: 10.1016/j.rdc.2007.11.003. View

Aldred M, Vijayakrishnan J, James V, Soubrier F, Gomez-Sanchez M, Martensson G . BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. Hum Mutat. 2006; 27(2):212-3. DOI: 10.1002/humu.9398. View

Rodriguez C, Gonzalez-Diez M, Badimon L, Martinez-Gonzalez J . Sphingosine-1-phosphate: A bioactive lipid that confers high-density lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin. Thromb Haemost. 2009; 101(4):665-73. View

Chalfant C, Spiegel S . Sphingosine 1-phosphate and ceramide 1-phosphate: expanding roles in cell signaling. J Cell Sci. 2005; 118(Pt 20):4605-12. DOI: 10.1242/jcs.02637. View

10.

Dingemanse J, Sidharta P, Maddrey W, Rubin L, Mickail H . Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Expert Opin Drug Saf. 2013; 13(3):391-405. DOI: 10.1517/14740338.2014.859674. View

11.

Voelkel N, Tuder R, Wade K, Hoper M, Lepley R, Goulet J . Inhibition of 5-lipoxygenase-activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats. J Clin Invest. 1996; 97(11):2491-8. PMC: 507334. DOI: 10.1172/JCI118696. View

12.

Peters-Golden M, Henderson Jr W . Leukotrienes. N Engl J Med. 2007; 357(18):1841-54. DOI: 10.1056/NEJMra071371. View

13.

Wright L, Tuder R, Wang J, Cool C, Lepley R, Voelkel N . 5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. Am J Respir Crit Care Med. 1998; 157(1):219-29. DOI: 10.1164/ajrccm.157.1.9704003. View

14.

Marder P, Sawyer J, Froelich L, Mann L, Spaethe S . Blockade of human neutrophil activation by 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5- hydroxyphenoxy]propoxy]phenoxy]benzoic acid (LY293111), a novel leukotriene B4 receptor antagonist. Biochem Pharmacol. 1995; 49(11):1683-90. DOI: 10.1016/0006-2952(95)00078-e. View

15.

Peters-Golden M, Brock T . 5-lipoxygenase and FLAP. Prostaglandins Leukot Essent Fatty Acids. 2003; 69(2-3):99-109. DOI: 10.1016/s0952-3278(03)00070-x. View

16.

Yokomizo T, Uozumi N, Takahashi T, Kume K, Izumi T, Shimizu T . Leukotriene A4 hydrolase and leukotriene B4 metabolism. J Lipid Mediat Cell Signal. 1995; 12(2-3):321-32. DOI: 10.1016/0929-7855(95)00041-n. View

17.

Cristol J, Provencal B, Sirois P . Leukotriene receptors. J Recept Res. 1989; 9(4-5):341-67. DOI: 10.3109/10799898909066063. View

18.

Muskardin D, Voelkel N, Fitzpatrick F . Modulation of pulmonary leukotriene formation and perfusion pressure by bestatin, an inhibitor of leukotriene A4 hydrolase. Biochem Pharmacol. 1994; 48(1):131-7. DOI: 10.1016/0006-2952(94)90232-1. View

19.

Tabata T, Ono S, Song C, Noda M, Suzuki S, Tanita T . [Role of leukotriene B4 in monocrotaline-induced pulmonary hypertension]. Nihon Kyobu Shikkan Gakkai Zasshi. 1997; 35(2):160-6. View

20.

Hsueh W, Sun F . Leukotriene B4 biosynthesis by alveolar macrophages. Biochem Biophys Res Commun. 1982; 106(4):1085-91. DOI: 10.1016/0006-291x(82)91223-2. View